Takeda To Help Develop Lundbeck's First-In-Class Mood Disorder Candidates In Japan, U.S.
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has taken a step to round out its pipeline by adding mood and anxiety disorder candidates under an agreement with Danish pharma H. Lundbeck
You may also be interested in...
Takeda Makes $1 Billion Move For Amgen Development Rights
Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion
Takeda Makes $1 Billion Move For Amgen Development Rights
Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion
Takeda Inks Deal To Develop Anti-Obesity Drugs With LG Life Sciences
Agreement is one of three announced by Takeda March 30, including a deal to develop cancer compounds with CanBas.
Need a specific report? 1000+ reports available
Buy Reports